Antagonism of the GCGR has been proposed as a pharmacological strategy for the treatment of both T1DM and T2DM, and can be achieved through several approaches, including small-molecule receptor antagonists, monoclonal antibodies (mAbs) targeting GCGR, and antisense oligonucleotides designed to downregulate receptor expression [46]. This evidence concerns the gene GCGR and type 1 diabetes mellitus.